Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2467880 | 0.78 | PARP1 (0.31) | PARP1TNKS2 | |
| SCHEMBL20567838 | 0.77 | PTK2 (0.56) | PARP1TNKS2 | |
| SCHEMBL15202700 | 0.77 | PTK2 (0.42) | PARP1TNKS2 | |
| SCHEMBL20568606 | 0.71 | CYP1A2 (0.45) | — | |
| SCHEMBL7689479 | 0.71 | CDC7 (0.61) | — | |
| SCHEMBL7683020 | 0.70 | PTK2 (0.57) | — | |
| SCHEMBL2471020 | 0.68 | ROCK2 (0.38) | PARP1TNKS2 | |
| SCHEMBL7481389 | 0.68 | ROCK2 (0.34) | PARP1TNKS2 | |
| SCHEMBL12336824 | 0.67 | TSHR (0.50) | — | |
| SCHEMBL14896315 | 0.67 | TNKS2 (0.46) | PARP1TNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417202-B1 | 3-ACETYL-4-METHYL-2,5-DI(4-PYRIDYL)-1H-PYRROLE, FOR EXAMPLE; TREATING CELL ADHESION MOLECULES (CAMS) MEDIATED DISEASES SUCH AS ARTHRITIS, AIDS, SEPTIC SHOCK, CACHEXIA, TRANSPLANT REJECTION | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | ICAM1, VCAM1, CD14 | PARP1 745/4885TNKS2 1793/4885PARP2 2289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.